PAHC
Price
$22.25
Change
+$2.86 (+14.75%)
Updated
May 8 closing price
Capitalization
523.71M
110 days until earnings call
TEVA
Price
$18.07
Change
+$0.47 (+2.67%)
Updated
May 8 closing price
Capitalization
15.06B
89 days until earnings call
Ad is loading...

PAHC vs TEVA

Header iconPAHC vs TEVA Comparison
Open Charts PAHC vs TEVABanner chart's image
Phibro Animal Health
Price$22.25
Change+$2.86 (+14.75%)
Volume$670.14K
Capitalization523.71M
Teva Pharmaceutical Industries
Price$18.07
Change+$0.47 (+2.67%)
Volume$19.84M
Capitalization15.06B
PAHC vs TEVA Comparison Chart
Loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAHC vs. TEVA commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Buy and TEVA is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (PAHC: $22.25 vs. TEVA: $18.07)
Brand notoriety: PAHC: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: PAHC: 267% vs. TEVA: 156%
Market capitalization -- PAHC: $523.71M vs. TEVA: $15.06B
PAHC [@Pharmaceuticals: Other] is valued at $523.71M. TEVA’s [@Pharmaceuticals: Other] market capitalization is $15.06B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 1 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • PAHC’s FA Score: 1 green, 4 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than PAHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 5 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 6 bearish.
  • TEVA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than PAHC.

Price Growth

PAHC (@Pharmaceuticals: Other) experienced а +19.62% price change this week, while TEVA (@Pharmaceuticals: Other) price change was +15.69% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.21%. For the same industry, the average monthly price growth was +11.99%, and the average quarterly price growth was +4.71%.

Reported Earning Dates

PAHC is expected to report earnings on Aug 27, 2025.

TEVA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.21% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($15.1B) has a higher market cap than PAHC($524M). PAHC has higher P/E ratio than TEVA: PAHC (34.11) vs TEVA (22.62). PAHC YTD gains are higher at: 6.483 vs. TEVA (-18.013). TEVA has higher annual earnings (EBITDA): 1.56B vs. PAHC (83.7M). TEVA has more cash in the bank: 3.23B vs. PAHC (92.5M). PAHC has less debt than TEVA: PAHC (513M) vs TEVA (20.2B). TEVA has higher revenues than PAHC: TEVA (15.8B) vs PAHC (982M).
PAHCTEVAPAHC / TEVA
Capitalization524M15.1B3%
EBITDA83.7M1.56B5%
Gain YTD6.483-18.013-36%
P/E Ratio34.1122.62151%
Revenue982M15.8B6%
Total Cash92.5M3.23B3%
Total Debt513M20.2B3%
FUNDAMENTALS RATINGS
PAHC vs TEVA: Fundamental Ratings
PAHC
TEVA
OUTLOOK RATING
1..100
2129
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
8247
SMR RATING
1..100
7792
PRICE GROWTH RATING
1..100
5941
P/E GROWTH RATING
1..100
6212
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for TEVA (72) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew somewhat faster than TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (47) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PAHC (82) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew somewhat faster than PAHC’s over the last 12 months.

PAHC's SMR Rating (77) in the Pharmaceuticals Major industry is in the same range as TEVA (92) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Price Growth Rating (41) in the Pharmaceuticals Generic industry is in the same range as PAHC (59) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew similarly to PAHC’s over the last 12 months.

TEVA's P/E Growth Rating (12) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PAHC (62) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew somewhat faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCTEVA
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
58%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
68%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
71%
Declines
ODDS (%)
Bearish Trend 8 days ago
71%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
70%
View a ticker or compare two or three
Ad is loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THGRX31.640.47
+1.51%
Thornburg Small/Mid Cap Growth R5
SNGRX23.18N/A
N/A
Sit International Growth
PSTAX19.70N/A
N/A
Virtus KAR Capital Growth A
NBPTX45.42N/A
N/A
Neuberger Berman Large Cap Value Tr
FEIAX32.30N/A
N/A
Fidelity Advisor Equity Income A

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with PBH. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then PBH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+14.75%
PBH - PAHC
47%
Loosely correlated
+6.92%
ZTS - PAHC
37%
Loosely correlated
+3.65%
ALKS - PAHC
33%
Poorly correlated
N/A
ELAN - PAHC
30%
Poorly correlated
+2.25%
AMPH - PAHC
29%
Poorly correlated
+0.90%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
+2.67%
AMRX - TEVA
35%
Loosely correlated
+3.32%
ELAN - TEVA
32%
Poorly correlated
+2.25%
PCRX - TEVA
28%
Poorly correlated
-1.07%
SNDL - TEVA
26%
Poorly correlated
+0.77%
ACET - TEVA
25%
Poorly correlated
-2.45%
More